NCT02564380 Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) Status TERMINATED Phase PHASE2
NCT02564263 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Status COMPLETED Phase PHASE3
NCT02563548 A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors Status COMPLETED Phase PHASE1
NCT02563002 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Status COMPLETED Phase PHASE3
NCT02560636 Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02559687 Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) Status COMPLETED Phase PHASE2
NCT02557321 PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02555657 Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Status COMPLETED Phase PHASE3
NCT02553499 Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) Status TERMINATED Phase PHASE1
NCT02546986 Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer Status TERMINATED Phase PHASE2
NCT02546531 Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer Status COMPLETED Phase PHASE1
NCT02541565 Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma Status COMPLETED Phase PHASE1
NCT02538510 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Status COMPLETED Phase PHASE1/PHASE2
NCT02530502 Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Status TERMINATED Phase PHASE1
NCT02528357 GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1) Status COMPLETED Phase PHASE1
NCT02521870 A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Status TERMINATED Phase PHASE1/PHASE2
NCT02521844 A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02520154 Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Status COMPLETED Phase PHASE2